Preprint Review Version 1 This version not peer reviewed

Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma

Version 1 : Received: 11 February 2018 / Approved: 12 February 2018 / Online: 12 February 2018 (05:13:18 CET)

How to cite: Chaturvedula, S.; Diver, D.J.; Vashist, A. Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma. Preprints 2018, 2018020084 (doi: 10.20944/preprints201802.0084.v1). Chaturvedula, S.; Diver, D.J.; Vashist, A. Dual Antiplatelet Therapy (DAPT) in Coronary Artery Disease: A Daunting Dilemma. Preprints 2018, 2018020084 (doi: 10.20944/preprints201802.0084.v1).

Abstract

Percutaneous coronary intervention(PCI) with stenting for the treatment of acute coronary syndrome(ACS) is the contemporary standard of care. Such treatment is followed by Dual anti-platelet therapy(DAPT) comprising of aspirin and a P2Y12 inhibitor. The efficacy of this therapy has been well established but the optimal duration of DAPT remains elusive, and has thus far attracted a prodigious deal of scientific attention. Decision regarding DAPT duration can be challenging clinically in the modern era with the evolution of newer stents, more potent antiplatelet agents and novel anticoagulant drugs in addition to an older patient population with multiple comorbidities. Major societal guidelines have emphasized comprehensive assessment of ischemic and bleeding risk, in turn recommending individualization of DAPT duration, thus encouraging "shared decision making". The following review is aimed at critically evaluating the available evidence to help make these crucial clinical decisions regarding duration of DAPT and triple therapy.

Subject Areas

dual anti platelet therapy; acute coronary syndrome; stents

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.